Back to Search
Start Over
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
- Source :
- JHEP reports, vol. 4, no. 1, pp. 100387, JHEP Reports, Vol 4, Iss 1, Pp 100387-(2022), JHEP reports, Vol. 4, no.1, p. 100387 [1-13] (2022), JHEP Reports
- Publication Year :
- 2022
-
Abstract
- Background & Aims Through FXR and TGR5 signaling, bile acids (BAs) modulate lipid and glucose metabolism, inflammation and fibrosis. Hence, BAs returning to the liver after enteric secretion, modification and reabsorption may contribute to the pathogenesis of non-alcoholic steatohepatitis (NASH). Herein, we characterized the enterohepatic profile and signaling of BAs in preclinical models of NASH, and explored the consequences of experimental manipulation of BA composition. Methods We used high-fat diet (HFD)-fed foz/foz and high-fructose western diet-fed C57BL/6J mice, and compared them to their respective controls. Mice received a diet supplemented with deoxycholic acid (DCA) to modulate BA composition. Results Compared to controls, mice with NASH had lower concentrations of BAs in their portal blood and bile, while systemic BA concentrations were not significantly altered. Notably, the concentrations of secondary BAs, and especially of DCA, and the ratio of secondary to primary BAs were strikingly lower in bile and portal blood of mice with NASH. Hence, portal blood was poor in FXR and TGR5 ligands, and conferred poor anti-inflammatory protection in mice with NASH. Enhanced primary BAs synthesis and conversion of secondary to primary BAs in NASH livers contributed to the depletion in secondary BAs. Dietary DCA supplementation in HFD-fed foz/foz mice restored the BA concentrations in portal blood, increased TGR5 and FXR signaling, improved the dysmetabolic status, protected from steatosis and hepatocellular ballooning, and reduced macrophage infiltration. Conclusions BA composition in the enterohepatic cycle, but not in systemic circulation, is profoundly altered in preclinical models of NASH, with specific depletion in secondary BAs. Dietary correction of the BA profile protected from NASH, supporting a role for enterohepatic BAs in the pathogenesis of NASH. Lay summary This study clearly demonstrates that the alterations of enterohepatic bile acids significantly contribute to the development of non-alcoholic steatohepatitis in relevant preclinical models. Indeed, experimental modulation of bile acid composition restored perturbed FXR and TGR5 signaling and prevented non-alcoholic steatohepatitis and associated metabolic disorders.<br />Graphical abstract<br />Highlights • The enterohepatic bile acid profile is profoundly altered in mice with NASH. • Bile acid signaling through FXR and TGR5 is dampened in mice with NASH. • Modulation of bile acid composition prevents obesity, insulin resistance and NASH.
- Subjects :
- HFD, high-fat diet
CYP7A1
CYP8B1, sterol 12α-hydroxylase
WDF, western and high-fructose diet
FABP6
OGTT, oral glucose tolerance test
FGF15
RC799-869
ASBT, apical sodium-dependent BA transporter
chemistry.chemical_compound
OST, organic solute transporter
βMCA, β-muricholic acid
SHP, small heterodimer protein
WDF
CYP27A1
SHP
TNFα
Immunology and Allergy
LCA, lithocholic acid
DCA
FABP6, fatty acid binding protein 6
FGFR4, fibroblast growth factor receptor 4
CA, cholic acid
NAS, NAFLD activity score
CA
CYP7B1
CYP7B1, oxysterol 7α-hydroxylase
Bile acid
WT
αMCA
ND, normal diet
TGR5, Takeda G-protein coupled receptor 5
Chemistry
LCA
Deoxycholic acid
TLCA
TGR5
Gastroenterology
NASH
GLP-1, glucagon-like peptide-1
Diseases of the digestive system. Gastroenterology
G protein-coupled bile acid receptor
TNFα, tumor necrosis factor α
FXR
BA, bile acid
LPS, lipopolysaccharide
Research Article
CYP2A12, bile acid 7α-hydroxylase
ωMCA
NAFLD, non-alcoholic fatty liver disease
medicine.medical_specialty
ωMCA, ω-muricholic acid
LPS
normal diet
Normal diet
βMCA
medicine.drug_class
NASH, non-alcoholic steatohepatitis
education
tumor necrosis factor α
BA
digestive system
metabolic syndrome
CDCA, chenodeoxycholic acid
CYP2A12
CYP27A1, sterol 27-hydroxylase
Internal medicine
NAFLD
Internal Medicine
medicine
OGTT
CYP7A1, cholesterol 7α-hydroxylase
DCA, deoxycholic acid
FGF15, fibroblast growth factor 15
FXR, Farnesoid X receptor
TLCA, tauro-lithocholic acid
WT, wild-type
αMCA, α-muricholic acid
wild-type
CYP8B1
Hepatology
OST
medicine.disease
Endocrinology
NAS
FGFR4
CDCA
HFD
ND
Steatohepatitis
GLP-1
ASBT
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- JHEP reports, vol. 4, no. 1, pp. 100387, JHEP Reports, Vol 4, Iss 1, Pp 100387-(2022), JHEP reports, Vol. 4, no.1, p. 100387 [1-13] (2022), JHEP Reports
- Accession number :
- edsair.doi.dedup.....a4f803f3cd8976e73d533d8b1885ead5